New drug review
Abstract
Several countries now classify new medicines in terms of their contribution to therapy. The Patented Medicines Pricing Review Board’s (PMPRB’s) system in Canada classifies medicines as ‘breakthroughs or offering substantial improvement’, ‘additions to a class providing moderate, little or no improvement’ or ‘line extensions’.
Published
2008-06-26
Issue
Section
Therapeutic
By submitting manuscripts to PNT, authors of original articles are assigning copyright to Medpharm Publications (Pty) Ltd. Authors may use their own work after publication without written permission, provided they acknowledge the original source. Individuals and academic institutions may freely copy and distribute articles published in PNT for educational and research purposes without obtaining permission.
